Novartis will spend $300 million to bolster its development and production capabilities for biologic medicines, which make up an increasing share of its drug pipeline.
The Swiss drugmaker will invest $110 million in clinical manufacturing capacity in Mengeš, Slovenia and $60 million in development manufacturing capacity at its Schaftenau campus in Austria, to better embed biologics development within existing facilities, it said Monday.
Novartis will also spend $100 million to establish a biologics hub near its Novartis Institutes of BioMedical Research biologics center in Switzerland to foster research and attract talent.
